Under Dr. Anil Bhansali's clinical leadership, Gini has built one of the most rigorous GLP-1 outcomes programmes in North India. Unlike commercial weight loss clinics that prescribe GLP-1 drugs based on patient demand, Gini's approach is data-driven — every patient is assessed against a metabolic phenotype framework, every outcome is tracked, and prescribing decisions are continuously refined based on what the data shows actually works for each patient type.
📍 Sector 69, Mohali · 0172 4120100 · Mon–Sat 10 AM–6 PM
GLP-1 drugs are powerful metabolic agents — not lifestyle supplements. Prescribing them without a complete metabolic workup puts patients at real clinical risk.
Tirzepatide and semaglutide work through different mechanisms and produce very different results depending on your fasting insulin, HOMA-IR, and metabolic phenotype. Prescribing without this data means guessing — and an expensive, potentially ineffective guess at that.
GLP-1 receptor agonists carry an FDA black box warning for medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia type 2 (MEN2). A personal or family history of these conditions is a hard contraindication. This must be screened before starting any GLP-1 drug.
GLP-1 agonists increase resting heart rate by 2–4 bpm on average. In patients with existing arrhythmias or undiagnosed cardiac disease, this matters. A cardiac baseline (ECG, and Echo/TMT where indicated) should precede GLP-1 initiation in patients with risk factors.
Rapid weight loss on GLP-1 drugs — especially without adequate protein intake and resistance activity — can result in significant muscle loss alongside fat loss. Regular monitoring distinguishes fat loss from lean mass loss. Dose escalation decisions require clinical oversight, not self-titration from YouTube.
All three are GLP-1-class drugs, but they are not interchangeable. The right choice depends on your metabolic profile, weight goal, and clinical history.
The most common question we get: "Should I take Mounjaro or Ozempic?" The honest answer: it depends on your metabolic profile. Under Dr. Bhansali's clinical leadership, we have tracked outcomes across all three major GLP-1 drugs and have developed a clear picture of which drug produces the best outcomes for which patient type.
As India's domestic GLP-1 market expands rapidly with new branded and generic entrants, our team is actively tracking outcomes data for newer molecules as they become available. We will update this page with real-world data as it emerges from our cohort. This is not marketing — it is clinical learning.
The GLP-1 market in India has changed dramatically since mid-2025. This reference covers all currently available branded and generic options. Consult Dr. Bhansali before starting any of these.
Following semaglutide patent expiry in March 2026, multiple Indian pharmaceutical companies have launched or are launching generic semaglutide. We are assessing these systematically. Pricing, quality, device design, and clinical equivalence vary — do not self-switch between brands without medical supervision.
We are actively evaluating domestic generic GLP-1 options as they enter the Indian market. Our criteria: bioequivalence data, device reliability, cold chain integrity, and manufacturer track record. We will only recommend generics that meet our clinical standards. Call 0172-4120100 for current recommendations.
GLP-1 therapy is not appropriate for everyone. Dr. Bhansali assesses every patient individually. This is a general guide — not a substitute for a clinical assessment.
GLP-1 therapy at Gini starts with a complete metabolic assessment. There is no shortcut to a safe, effective prescription.
HbA1c, fasting insulin, HOMA-IR, lipid profile, kidney function (creatinine, eGFR, urine microalbumin), liver enzymes, thyroid (TSH). This determines your metabolic type and the right drug.
Echo and TMT if indicated by risk factors. GLP-1 drugs affect heart rate and cardiovascular function. Baseline cardiac data ensures safe initiation and enables tracking of cardiac benefit over time.
Based on your metabolic profile, weight goal, cost tolerance, and injection preference. Dr. Bhansali explains the evidence for each option and gives a clear clinical rationale for the recommendation.
Starting dose, escalation schedule, and side effect monitoring protocol. GI side effects (nausea, vomiting) are common in the first weeks — the titration plan minimises these while still reaching therapeutic dose.
Quarterly data entry into Dr. Bhansali's GLP-1 cohort. Your outcomes contribute to real-world evidence that helps the next patient make a better decision. This is what separates Gini's programme from a simple prescription service.
The following data is drawn from Dr. Bhansali's GLP-1 patient cohort tracked at Gini Hospital. These are real-world outcomes — not clinical trial results from controlled populations. Real-world results are typically somewhat lower than trial data due to adherence variation, comorbidity complexity, and dose adjustments for tolerability. We believe in publishing honest outcomes, not aspirational numbers.
Many CGHS patients at Gini use their coverage for monitoring (significantly reducing ongoing costs) while paying for the drug itself privately. Dr. Bhansali advises on which drug gives the best value for money given your clinical situation. For reimbursement queries: call our CGHS desk at 0172-4120100.
Data-driven. Endocrinologist-led. 1,200+ patients tracked. Not a weight loss clinic — a clinical programme built on real outcomes data. Mon–Sat, 10 AM–6 PM.